These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 4047258)

  • 1. Prognostic significance of stratification systems in multiple myeloma. I. Risk categories (good and poor risk).
    Scudla V; Indrák K
    Neoplasma; 1985; 32(4):469-79. PubMed ID: 4047258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of stratification systems in multiple myeloma. II. Clinical staging systems.
    Scudla V; Indrák K
    Neoplasma; 1985; 32(4):481-93. PubMed ID: 4047259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy.
    Scudla V; Zemanova M; Minarik J; Bacovsky J; Ordeltova M; Indrak K; Budikova M; Dusek L; Farbiakova V
    Neoplasma; 2006; 53(4):277-84. PubMed ID: 16830053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparative study of 2 prognostic classification systems for myeloma and examination of the correlation between initial bone marrow plasmacytosis and prognosis. A propos of a homogeneous population of 50 patients followed from diagnosis to death].
    Pesce A; Cassuto JP; Grisot C; Gratecos N; Bayle J; Viot G; Dujardin P
    Nouv Rev Fr Hematol (1978); 1983; 25(5):311-7. PubMed ID: 6657481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
    Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classification and prognostic evaluation in multiple myeloma. A retrospective study of relationship of survivals and responses to chemotherapy to immunological types, 20 single prognostic factors, 15 clinical staging systems, and 6 morphological classifications.
    Pasqualetti P; Colantonio D; Collacciani A; Casale R; Natali G
    Panminerva Med; 1991; 33(2):93-110. PubMed ID: 1923560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [BUN, Bence Jones protein, and chromosomal aberrations predict survival in multiple myeloma].
    Okada K; Oguchi N; Shinohara K; Tamura N; Ishii K; Noguchi Y; Hayashi S; Yamamoto H; Takeichi M; Fujimoto H; Shirota T; Hayashi T
    Rinsho Ketsueki; 1997 Dec; 38(12):1254-62. PubMed ID: 9455144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long-term survival and prognostic factors in multiple myeloma treated with conventional chemotherapy. Report of 109 cases].
    Ben Abid H; Meddeb B; Ben Abdallah M; Bel Hadj Ali Z; Hafsia R; Ben Lakhal R; Gouider E; Aissaoui L; Landoulsi I; ben Abdeladhim A; Hafsia A
    Tunis Med; 2000 Dec; 78(12):705-12. PubMed ID: 11155374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of two staging systems for myeloma.
    Vercelli D; Cozzolino F; Di Guglielmo R
    Nouv Rev Fr Hematol (1978); 1981; 23(2):107-10. PubMed ID: 7290984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A comparison of staging classifications of plasmacytoma].
    Löffler H; Gassmann W; Haferlach T; Pralle H
    Onkologie; 1986 Aug; 9(4):196, 199-201. PubMed ID: 3531946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple myeloma index: verification of a new prognostic approach with evaluation of treatment response.
    Bettini R; Tonolini M; Bernasconi M
    Haematologica; 1998 Aug; 83(8):708-13. PubMed ID: 9793254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International staging system for multiple myeloma.
    Greipp PR; San Miguel J; Durie BG; Crowley JJ; Barlogie B; Bladé J; Boccadoro M; Child JA; Avet-Loiseau H; Kyle RA; Lahuerta JJ; Ludwig H; Morgan G; Powles R; Shimizu K; Shustik C; Sonneveld P; Tosi P; Turesson I; Westin J
    J Clin Oncol; 2005 May; 23(15):3412-20. PubMed ID: 15809451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
    Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
    Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic value of the new international staging system in multiple myeloma. Comparison with Durie-Salmon staging system].
    Conté L G; Figueroa M G; Lois V V; Cabrera C ME; León R A; García L H; Rojas R H
    Rev Med Chil; 2008 Jan; 136(1):7-12. PubMed ID: 18483648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone.
    Cavagnaro F; Lein JM; Pavlovsky S; Becherini JO; Pileggi JE; Micheo EQ; Jait C; Musso A; Suárez A; Pizzolato M
    Cancer Treat Rep; 1980 Jan; 64(1):73-9. PubMed ID: 6991106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic factors affecting survival in multiple myeloma].
    Tornóczky J; Tóth A; Sziládi E; Hoffmann E; Liszátz M
    Orv Hetil; 1990 Aug; 131(31):1679-84. PubMed ID: 2205822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.
    Anagnostopoulos A; Aleman A; Ayers G; Donato M; Champlin R; Weber D; Alexanian R; Giralt S
    Cancer; 2004 Jun; 100(12):2607-12. PubMed ID: 15197803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of plasma cell propidium iodide and annexin-V indices and their mutual ratio in multiple myeloma.
    Scudla V; Ordeltova M; Minarik J; Dusek L; Zemanova M; Bacovsky J
    Neoplasma; 2006; 53(3):213-8. PubMed ID: 16652190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.
    Harousseau JL; Avet-Loiseau H; Attal M; Charbonnel C; Garban F; Hulin C; Michallet M; Facon T; Garderet L; Marit G; Ketterer N; Lamy T; Voillat L; Guilhot F; Doyen C; Mathiot C; Moreau P
    J Clin Oncol; 2009 Dec; 27(34):5720-6. PubMed ID: 19826130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.